Anandamide

Anandamide is a lipid of Fatty Acyls (FA) class. Anandamide is associated with abnormalities such as Dehydration. The involved functions are known as Process, Phenomenon, Phosphorylation, Catabolic Process and Gene Expression. Anandamide often locates in Nuchal region, Microglial and Hepatic. The associated genes with Anandamide are SGPL1 gene, SPTLC1 gene, RPSA gene, KDSR gene and SMPD1 gene. The related lipids are Sphingolipids, Lipopolysaccharides, Lysophospholipids, LYSO-PC and lysophosphatidylethanolamine.

Cross Reference

Introduction

To understand associated biological information of Anandamide, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Anandamide?

Anandamide is suspected in Dehydration and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Anandamide

MeSH term MeSH ID Detail
Alzheimer Disease D000544 76 associated lipids
Anorexia D000855 8 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Ataxia D001259 20 associated lipids
Urinary Bladder Diseases D001745 4 associated lipids
Body Weight D001835 333 associated lipids
Bradycardia D001919 13 associated lipids
Brain Concussion D001924 5 associated lipids
Brain Damage, Chronic D001925 6 associated lipids
Brain Edema D001929 20 associated lipids
Breast Neoplasms D001943 24 associated lipids
Bronchial Spasm D001986 18 associated lipids
Bulimia D002032 3 associated lipids
Cardiomyopathy, Dilated D002311 15 associated lipids
Catalepsy D002375 30 associated lipids
Celiac Disease D002446 16 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Cough D003371 19 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Edema D004487 152 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Epilepsy D004827 35 associated lipids
Fatty Liver D005234 48 associated lipids
Fever D005334 35 associated lipids
Fibromyalgia D005356 4 associated lipids
Glioma D005910 112 associated lipids
Hepatitis D006505 11 associated lipids
Hyperalgesia D006930 42 associated lipids
Hyperemia D006940 25 associated lipids
Hyperinsulinism D006946 27 associated lipids
Hyperkinesis D006948 11 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Hypertension D006973 115 associated lipids
Hypertension, Portal D006975 12 associated lipids
Hypotension D007022 41 associated lipids
Hypothermia D007035 19 associated lipids
Inflammation D007249 119 associated lipids
Insulin Resistance D007333 99 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Learning Disorders D007859 11 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Melanoma D008545 69 associated lipids
Memory Disorders D008569 33 associated lipids
Migraine Disorders D008881 11 associated lipids
Morphine Dependence D009021 9 associated lipids
Multiple Sclerosis D009103 13 associated lipids
Muscle Spasticity D009128 5 associated lipids
Mycoses D009181 18 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Neoplasms D009369 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Nerve Degeneration D009410 53 associated lipids
Nervous System Diseases D009422 37 associated lipids
Neuralgia D009437 28 associated lipids
Neuroblastoma D009447 66 associated lipids
Obesity D009765 29 associated lipids
Pain D010146 64 associated lipids
Parkinson Disease, Secondary D010302 17 associated lipids
Peptic Ulcer D010437 19 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Picornaviridae Infections D010850 4 associated lipids
Pregnancy, Ectopic D011271 5 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Schistosomiasis japonica D012554 3 associated lipids
Seizures D012640 87 associated lipids
Shock, Septic D012772 11 associated lipids
Sleep Deprivation D012892 5 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Stomach Ulcer D013276 75 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Urinary Incontinence D014549 4 associated lipids
Ventricular Fibrillation D014693 16 associated lipids
Reperfusion Injury D015427 65 associated lipids
Weight Gain D015430 101 associated lipids
Ocular Hypotension D015814 2 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Cholangiocarcinoma D018281 7 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Impotence, Vasculogenic D018783 4 associated lipids
Pancreatitis, Acute Necrotizing D019283 18 associated lipids
Endotoxemia D019446 27 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Substance-Related Disorders D019966 2 associated lipids
Sleep Apnea, Obstructive D020181 9 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Amnesia, Anterograde D020324 2 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Somatosensory Disorders D020886 1 associated lipids
Sleep Disorders, Intrinsic D020919 1 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Per page 10 20 50 100 | Total 105

PubChem Associated disorders and diseases

What pathways are associated with Anandamide

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Anandamide?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Anandamide?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Anandamide?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Anandamide?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Anandamide?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Anandamide

Download all related citations
Per page 10 20 50 100 | Total 2222
Authors Title Published Journal PubMed Link
Walker VJ et al. Metabolism of Anandamide by Human Cytochrome P450 2J2 in the Reconstituted System and Human Intestinal Microsomes. 2016 J. Pharmacol. Exp. Ther. pmid:27000802
Porter AC et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. 2002 J. Pharmacol. Exp. Ther. pmid:12023533
Darmani NA The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids. 2002 J. Pharmacol. Exp. Ther. pmid:11752094
Appendino G et al. Development of the first ultra-potent "capsaicinoid" agonist at transient receptor potential vanilloid type 1 (TRPV1) channels and its therapeutic potential. 2005 J. Pharmacol. Exp. Ther. pmid:15356216
Patel S et al. Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity. 2003 J. Pharmacol. Exp. Ther. pmid:12808005
Lichtman AH et al. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. 2004 J. Pharmacol. Exp. Ther. pmid:15229230
Snider NT et al. The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6. 2008 J. Pharmacol. Exp. Ther. pmid:18698000
McDougle DR et al. Endocannabinoids anandamide and 2-arachidonoylglycerol are substrates for human CYP2J2 epoxygenase. 2014 J. Pharmacol. Exp. Ther. pmid:25277139
Fride E et al. Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol. 1995 J. Pharmacol. Exp. Ther. pmid:7853184
Miller LL et al. Effects of alterations in cannabinoid signaling, alone and in combination with morphine, on pain-elicited and pain-suppressed behavior in mice. 2012 J. Pharmacol. Exp. Ther. pmid:22514333
Adams IB et al. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. 1995 J. Pharmacol. Exp. Ther. pmid:7791088
Welch SP et al. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception. 1995 J. Pharmacol. Exp. Ther. pmid:7791096
Ishioka N and Bukoski RD A role for N-arachidonylethanolamine (anandamide) as the mediator of sensory nerve-dependent Ca2+-induced relaxation. 1999 J. Pharmacol. Exp. Ther. pmid:10087011
Matias I et al. Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. 2004 J. Pharmacol. Exp. Ther. pmid:14757851
Akerman S et al. Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. 2004 J. Pharmacol. Exp. Ther. pmid:14718591
Trezza V and Vanderschuren LJ Divergent effects of anandamide transporter inhibitors with different target selectivity on social play behavior in adolescent rats. 2009 J. Pharmacol. Exp. Ther. pmid:18948500
McVey DC et al. Endocannabinoids induce ileitis in rats via the capsaicin receptor (VR1). 2003 J. Pharmacol. Exp. Ther. pmid:12538826
McAllister SD et al. Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a xenopus oocyte expression system. 1999 J. Pharmacol. Exp. Ther. pmid:10525080
Glaser ST and Kaczocha M Cyclooxygenase-2 mediates anandamide metabolism in the mouse brain. 2010 J. Pharmacol. Exp. Ther. pmid:20702753
McCollum L et al. Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells. 2007 J. Pharmacol. Exp. Ther. pmid:17379772
Wang Y et al. Endocannabinoid regulates blood pressure via activation of the transient receptor potential vanilloid type 1 in Wistar rats fed a high-salt diet. 2007 J. Pharmacol. Exp. Ther. pmid:17308041
Showalter VM et al. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. 1996 J. Pharmacol. Exp. Ther. pmid:8819477
Fegley D et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. 2005 J. Pharmacol. Exp. Ther. pmid:15579492
Lake KD et al. Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. 1997 J. Pharmacol. Exp. Ther. pmid:9190833
Willoughby KA et al. The biodisposition and metabolism of anandamide in mice. 1997 J. Pharmacol. Exp. Ther. pmid:9223560
Hillard CJ Endocannabinoids and vascular function. 2000 J. Pharmacol. Exp. Ther. pmid:10871291
Song ZH and Zhong M CB1 cannabinoid receptor-mediated cell migration. 2000 J. Pharmacol. Exp. Ther. pmid:10871313
Di Marzo V et al. A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid. 2002 J. Pharmacol. Exp. Ther. pmid:11861807
Glaser ST et al. Ex vivo imaging of fatty acid amide hydrolase activity and its inhibition in the mouse brain. 2006 J. Pharmacol. Exp. Ther. pmid:16278311
Adams IB et al. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. 1998 J. Pharmacol. Exp. Ther. pmid:9495885
Fowler CJ et al. Ibuprofen inhibits rat brain deamidation of anandamide at pharmacologically relevant concentrations. Mode of inhibition and structure-activity relationship. 1997 J. Pharmacol. Exp. Ther. pmid:9353392
Li G et al. Protective Action of Anandamide and Its COX-2 Metabolite against l-Homocysteine-Induced NLRP3 Inflammasome Activation and Injury in Podocytes. 2016 J. Pharmacol. Exp. Ther. pmid:27189966
Thomas KC et al. Transient receptor potential vanilloid 1 agonists cause endoplasmic reticulum stress and cell death in human lung cells. 2007 J. Pharmacol. Exp. Ther. pmid:17332266
Chiba T et al. A synthetic cannabinoid, CP55940, inhibits lipopolysaccharide-induced cytokine mRNA expression in a cannabinoid receptor-independent mechanism in rat cerebellar granule cells. 2011 J. Pharm. Pharmacol. pmid:21492165
Hayase T et al. Protective effects of cannabinoid receptor agonists against cocaine and other convulsant-induced toxic behavioural symptoms. 2001 J. Pharm. Pharmacol. pmid:11732755
Di Marzo M et al. Synthesis, conformational analysis and CB1 binding affinity of hairpin-like anandamide pseudopeptide mimetics. 2006 J. Pept. Sci. pmid:16534762
Gómez R et al. Endogenous cannabinoid anandamide impairs cell growth and induces apoptosis in chondrocytes. 2014 J. Orthop. Res. pmid:24902823
Hutchins-Wiese HL et al. Hind limb suspension and long-chain omega-3 PUFA increase mRNA endocannabinoid system levels in skeletal muscle. 2012 J. Nutr. Biochem. pmid:22051448
Battista N et al. Abnormal anandamide metabolism in celiac disease. 2012 J. Nutr. Biochem. pmid:22209002
Hutchins HL et al. Eicosapentaenoic acid decreases expression of anandamide synthesis enzyme and cannabinoid receptor 2 in osteoblast-like cells. 2011 J. Nutr. Biochem. pmid:20951563
Mennella I et al. Food Liking Enhances the Plasma Response of 2-Arachidonoylglycerol and of Pancreatic Polypeptide upon Modified Sham Feeding in Humans. 2015 J. Nutr. pmid:26180248
Batetta B et al. Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. 2009 J. Nutr. pmid:19549757
Thomas EA et al. Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the rat central nervous system. 1997 J. Neurosci. Res. pmid:9452020
Bari M et al. Cholesterol-dependent modulation of type 1 cannabinoid receptors in nerve cells. 2005 J. Neurosci. Res. pmid:15920744
Molina-Holgado F et al. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. 2002 J. Neurosci. Res. pmid:11891798
Arias-Carrión O et al. Biochemical modulation of the sleep-wake cycle: endogenous sleep-inducing factors. 2011 J. Neurosci. Res. pmid:21557294
Bajo M et al. Differential alteration of hippocampal excitatory synaptic transmission by cannabinoid ligands. 2009 J. Neurosci. Res. pmid:18816788
Shinjyo N et al. Impact of omega-6 polyunsaturated fatty acid supplementation and γ-aminobutyric acid on astrogliogenesis through the endocannabinoid system. 2013 J. Neurosci. Res. pmid:23633391
Bannerman P et al. Early migratory rat neural crest cells express functional gap junctions: evidence that neural crest cell survival requires gap junction function. 2000 J. Neurosci. Res. pmid:10972957
Ahern GP et al. Extracellular cations sensitize and gate capsaicin receptor TRPV1 modulating pain signaling. 2005 J. Neurosci. pmid:15917451
Tabatadze N et al. Sex Differences in Molecular Signaling at Inhibitory Synapses in the Hippocampus. 2015 J. Neurosci. pmid:26269634
Gómez R et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. 2002 J. Neurosci. pmid:12417686
Gray JM et al. Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety. 2015 J. Neurosci. pmid:25740517
Wang ZJ et al. Cannabinoid receptor-mediated regulation of neuronal activity and signaling in glomeruli of the main olfactory bulb. 2012 J. Neurosci. pmid:22723687
Xiong W et al. A common molecular basis for exogenous and endogenous cannabinoid potentiation of glycine receptors. 2012 J. Neurosci. pmid:22496565
Franklin A et al. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. 2003 J. Neurosci. pmid:12944505
Shen Y et al. A transient receptor potential-like channel mediates synaptic transmission in rod bipolar cells. 2009 J. Neurosci. pmid:19439586
Derkinderen P et al. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. 2003 J. Neurosci. pmid:12657697
Clement AB et al. Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. 2003 J. Neurosci. pmid:12736361
Marinelli S et al. Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. 2003 J. Neurosci. pmid:12716921
Massa F et al. Alterations in the hippocampal endocannabinoid system in diet-induced obese mice. 2010 J. Neurosci. pmid:20445053
Tognetto M et al. Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. 2001 J. Neurosci. pmid:11160380
Cadas H et al. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. 1996 J. Neurosci. pmid:8656287
van der Stelt M et al. Exogenous anandamide protects rat brain against acute neuronal injury in vivo. 2001 J. Neurosci. pmid:11698588
Beltramo M et al. Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. 2000 J. Neurosci. pmid:10777802
Lerner TN et al. Endocannabinoid signaling mediates psychomotor activation by adenosine A2A antagonists. 2010 J. Neurosci. pmid:20147543
Garami A et al. Thermoregulatory phenotype of the Trpv1 knockout mouse: thermoeffector dysbalance with hyperkinesis. 2011 J. Neurosci. pmid:21289181
Justinova Z et al. The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys. 2005 J. Neurosci. pmid:15944392
Subbanna S et al. Anandamide-CB1 receptor signaling contributes to postnatal ethanol-induced neonatal neurodegeneration, adult synaptic, and memory deficits. 2013 J. Neurosci. pmid:23575834
Dinis P et al. Anandamide-evoked activation of vanilloid receptor 1 contributes to the development of bladder hyperreflexia and nociceptive transmission to spinal dorsal horn neurons in cystitis. 2004 J. Neurosci. pmid:15601931
Akerman S et al. Endocannabinoids in the brainstem modulate dural trigeminovascular nociceptive traffic via CB1 and "triptan" receptors: implications in migraine. 2013 J. Neurosci. pmid:24027286
Ade KK and Lovinger DM Anandamide regulates postnatal development of long-term synaptic plasticity in the rat dorsolateral striatum. 2007 J. Neurosci. pmid:17329438
Khlaifia A et al. Anandamide, cannabinoid type 1 receptor, and NMDA receptor activation mediate non-Hebbian presynaptically expressed long-term depression at the first central synapse for visceral afferent fibers. 2013 J. Neurosci. pmid:23904599
Kim D and Thayer SA Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture. 2001 J. Neurosci. pmid:11319244
Khasabova IA et al. A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. 2008 J. Neurosci. pmid:18971457
Veldhuis WB et al. Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases. 2003 J. Neurosci. pmid:12764100
Cadas H et al. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. 1997 J. Neurosci. pmid:9006968
Khasabova IA et al. Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. 2012 J. Neurosci. pmid:22593077
Qin N et al. TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. 2008 J. Neurosci. pmid:18550765
Chemin J et al. Neuronal T-type alpha 1H calcium channels induce neuritogenesis and expression of high-voltage-activated calcium channels in the NG108-15 cell line. 2002 J. Neurosci. pmid:12177183
Gubellini P et al. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. 2002 J. Neurosci. pmid:12177188
Kim SR et al. Transient receptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and in vitro. 2005 J. Neurosci. pmid:15659603
Ali AB Presynaptic Inhibition of GABAA receptor-mediated unitary IPSPs by cannabinoid receptors at synapses between CCK-positive interneurons in rat hippocampus. 2007 J. Neurophysiol. pmid:17567776
Fischbach T et al. Effects of anandamide and noxious heat on intracellular calcium concentration in nociceptive drg neurons of rats. 2007 J. Neurophysiol. pmid:17581853
Uhelski ML et al. Inhibition of anandamide hydrolysis attenuates nociceptor sensitization in a murine model of chemotherapy-induced peripheral neuropathy. 2015 J. Neurophysiol. pmid:25505113
Fan P Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. 1995 J. Neurophysiol. pmid:7760148
Fisyunov A et al. Cannabinoids modulate the P-type high-voltage-activated calcium currents in purkinje neurons. 2006 J. Neurophysiol. pmid:16738209
De-May CL and Ali AB Cell type-specific regulation of inhibition via cannabinoid type 1 receptors in rat neocortex. 2013 J. Neurophysiol. pmid:23054605
Morisset V and Urban L Cannabinoid-induced presynaptic inhibition of glutamatergic EPSCs in substantia gelatinosa neurons of the rat spinal cord. 2001 J. Neurophysiol. pmid:11431486
Twitchell W et al. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. 1997 J. Neurophysiol. pmid:9242259
Contassot E et al. Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1. 2004 J. Neuropathol. Exp. Neurol. pmid:15453094
Jean-Gilles L et al. Plasma endocannabinoid levels in multiple sclerosis. 2009 J. Neurol. Sci. pmid:19695579
Di Filippo M et al. Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis. 2008 J. Neurol. Neurosurg. Psychiatr. pmid:18535023
Stefano GB Autoimmunovascular regulation: morphine and anandamide and ancondamide stimulated nitric oxide release. 1998 J. Neuroimmunol. pmid:9610675
Eisenstein TK et al. Anandamide and Delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors. 2007 J. Neuroimmunol. pmid:17640739
Schwarz H et al. Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. 1994 J. Neuroimmunol. pmid:7962480
De Laurentiis A et al. The hypothalamic endocannabinoid system participates in the secretion of oxytocin and tumor necrosis factor-alpha induced by lipopolysaccharide. 2010 J. Neuroimmunol. pmid:20207018
Hollis JH et al. The endocannabinoid arachidonylethanolamide attenuates aspects of lipopolysaccharide-induced changes in energy intake, energy expenditure and hypothalamic Fos expression. 2011 J. Neuroimmunol. pmid:21262543
Malfitano AM et al. Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis. 2006 J. Neuroimmunol. pmid:16239036
Bisogno T Endogenous cannabinoids: structure and metabolism. 2008 J. Neuroendocrinol. pmid:18426492